Supernus Pharmaceuticals Inc  

(Public, NASDAQ:SUPN)   Watch this stock  
Find more results for William M. Vaughn, III.�
+0.07 (0.85%)
Apr 17 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 8.02 - 8.48
52 week 4.45 - 10.55
Open 8.14
Vol / Avg. 253,358.00/604,266.00
Mkt cap 347.29M
P/E     -
Div/yield     -
EPS -2.91
Shares 42.04M
Beta     -
Inst. own 86%
May 22, 2014
Supernus Pharmaceuticals Annual Meeting of the Stockholders - 10:00AM EDT - Add to calendar
May 8, 2014
Q1 2014 Supernus Pharmaceuticals Earnings Release (Estimated) Add to calendar
Mar 13, 2014
Q4 2013 Supernus Pharmaceuticals Earnings Conference Call
Mar 12, 2014
Q4 2013 Supernus Pharmaceuticals Earnings Release
Mar 3, 2014
Supernus Pharmaceuticals at Cowen Health Care Conference
Feb 26, 2014
Supernus Pharmaceuticals at RBC Capital Markets Healthcare Conference
Feb 25, 2014
Supernus Pharmaceuticals at Citi Global Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '13) 2013
Net profit margin -216.82% -767.73%
Operating margin -191.07% -594.64%
EBITD margin - -509.01%
Return on average assets -76.56% -90.03%
Return on average equity -391.45% -202.72%
Employees 235 -
CDP Score - -


1550 East Gude Drive
United States - Map
+1-301-8382500 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Supernus Pharmaceuticals, Inc. (Supernus) is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Supernus is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder (ADHD). Supernus�s two epilepsy product candidates are SPN-538 and Epliga. Epliga is in Phase III clinical trials. Supernus ADHD product candidates include SPN-810 (molindone hydrochloride), a treatment for impulsive aggression in patients with ADHD, and SPN-812, a non-stimulant treatment for ADHD. Both of these programs are in Phase II. In addition to these four products candidates, Supernus has several additional product candidates in various stages of development, including SPN-809. Its wholly owned subsidiary includes TCD Royalty Sub LLC.

Officers and directors

M. James Barrett Ph.D. Independent Chairman of the Board
Age: 70
Bio & Compensation  - Reuters
Jack A. Khattar President, Chief Executive Officer, Secretary, Director
Age: 51
Bio & Compensation  - Reuters
Gregory S. Patrick Chief Financial Officer, Vice President
Age: 61
Bio & Compensation  - Reuters
Stefan K.F. Schwabe M.D., Ph.D. Executive Vice-President - Research & Development, Chief Medical Officer
Age: 60
Bio & Compensation  - Reuters
Padmanabh P. Bhatt Ph.D. Senior Vice President- Intellectual Property, Chief Scientific Officer
Age: 55
Bio & Compensation  - Reuters
Victor Vaughn Senior Vice President - Sales
Age: 55
Bio & Compensation  - Reuters
Jones W. Bryan Ph.D. Vice President - Business Development
Age: 48
Bio & Compensation  - Reuters
Frederick M. Hudson Independent Director
Age: 67
Bio & Compensation  - Reuters
Charles W. Newhall III Independent Director
Age: 68
Bio & Compensation  - Reuters
William A. Nuerge Independent Director
Age: 60
Bio & Compensation  - Reuters